Page 31 - Management of Advanced Urothelial Carcinoma: Emerging Therapies and Biomarkers

Management of Central Serous Retinopathy whilst on Erdafitinib

Central Serous Retinopathy/Retinal Pigment Epithelial Detachment

• Withhold until resolution
Asymptomatic; • If resolves within 4 weeks, resume at next lower dose level
clinical or diagnostic observations • If no recurrence for 1 month, consider re-escalation
only • If stable for 2 consecutive eye exams but not resolved, resume
at next lower dose level

Visual acuity 20/40 or better or ≤3 • Withhold until resolution
lines of decreased vision from
baseline • If resolves within 4 weeks, may resume at next lower dose level

Visual acuity worse than 20/40 or • Withhold until resolution
>3 lines of decreased vision from • If resolves within 4 weeks, may resume 2 dose levels lower
baseline • If recurs, consider permanent discontinuation

Visual acuity 20/200 or worse in
affected eye • Permanently discontinue

Janssen Inc. Product Monograph: Balversa. Janssen Canada Inc; 2019